Welcome to the Weiner Research Lab
Precision Oncology
Lab objective
Merge patient data with highly annotated genomics to advance our ability to individualize cancer care
“Deliver the right cancer treatment to the right patient at the right dose and the right time.”
-Schwartzberg et al. 2017 ASCO Educational Book
Summer 2025 Weiner lab photo
Left to right: Adam Weiner (PI); Katie Kim (Intern); Elysh Chae (Intern); Jiyoun Seo (Post-doctoral fellow); Cece Garcia (Intern); Pranav Movva (Research associate)
Support Our Research
Your generous contribution directly funds our precision oncology research at Cedars-Sinai, helping advance individualized cancer care for patients with prostate cancer.
Make a GiftImportant On the donation page, please type "Adam Weiner, MD Research" in the "Leave a Comment" box to ensure your gift is directed to our lab.
Cedars-Sinai Medical Center is a 501(c)(3) nonprofit organization (Tax ID 95-1644600).
Your donation is tax-deductible to the fullest extent allowed by law.
You will receive a receipt for your records.
Inquire about Dr. Weiner’s research
Please fill out this form
Current research funding
1. Weiner AB. Unseen Scars. JAMA. 2025 Oct 28;334(16):1425. PMID: 40965874
2. Yang Y. Wang T. Fry J. Li Y. Meng Q. ... Weiner AB. Schaeffer EM. Liu Y. Dehm S. Cao Q. Tumor-specific lncRNA IGF1R-AS1 trans-regulates chromatin interactions associated with oncogenic MYC signaling. Nat Commun. 2026 Mar 19. PMID: 41857039
3. Weiner AB. Richardson S. Wilhalme H. Bailey AV. Kwan L. ... Litwin MS. Predicting patient-reported outcomes following treatment for localized prostate cancer: Model development and evaluation in an international cohort study. Clin Genitourin Cancer. 2026 Mar;24(2):102504. PMID: 41654456
4. Agrawal R. Weiner AB. Livingstone J. ... Boutros PC. Rettig MB. Reiter RE. Neoadjuvant anti-androgen therapy with or without MEK or SRC inhibition for unfavorable-risk prostate cancer: A Phase II randomized clinical trial. Eur Urol Oncol. 2025 Nov 8:S2588-9311(25)00287-1. PMID: 41207813
5. Weiner AB. Proudfoot JA. Aker M. Cardenas M. ... Brisbane WG. Marks LS. Genomic biomarker for prostate cancer focal therapy: Post hoc assessment of a phase II clinical trial. JCO Precis Oncol. 2025 Sep:9:e2500535. PMID: 40961406
6. Rizzo AS. Kanabur P. Weiner AB. What’s in a Name? Why Differentiation between BCR and Metastatic Prostate Cancer Matters. Curr Opin Urol. 2025 Sep 1;35(5):535-540. PMID: 40625123
7. Grant RS. Kakani P. Movva P. Daskivich TJ. Raman SS. Sisk AE. Brisbane WG. Reiter RE. Weiner AB. Identifying Cribriform and Intraductal Histology on MRI-assisted Biopsy for Patients with Intermediate Grade Prostate Cancer: Implications for Active Surveillance. Cancer. 2025 Jul 15;131(14):e35968. PMID: 40614127
8. Handa N. Li E. Proudfoot JA. Weiner AB. ... Schaeffer EM. Ross R. Prevalence of Potential Candidates for Targeted Therapies According to Treatment-related Transcriptomic Signatures Among 140,548 Patients with Nonmetastatic Prostate Cancer. Eur Urol Oncol. 2025 Aug;8(4):1050-1058. PMID: 40350343
9. Yang Y. Wang T. Ren Y. Weiner AB. Liu Q. Yum C. Wang R. Li Q. Lotan TL. Schaeffer EM. Yang R. Cao Q. Androgen receptor-regulated lncRNA PRCAT71 promotes AR signaling through the interaction with KHSRP in prostate cancer. Sci Adv. 2025 Apr 11;11(15). PMID: 40203114
10. Weiner AB. Ells Z. Meyer C. Dahlbom M. Sennung D. Varughese D. Ludwig VB. Carlucci G. Grant R. Czernin J. Calais J. Reiter RE. Clinical responses to PSMA radioguided salvage lymphadenectomy for prostate cancer recurrence: Results from a prospective exploratory trial. Eur Urol Open Sci. 2024 Oct 15:70:36-42. PMID: 39483519
11. Weiner AB. Agrawal R. Wang NK. Sonni I. Li E. Arbet J. Zhang J. Proudfoot JA. Hong BH. Davicioni E. Kane K. Valle L. Kishan AU. Dal Pra A. Ghadjar P. Sweeney CJ. Nickols NG. Karnes RJ. Shen J. Rettig MB. Czernin J. Ross AE. Chua MLK. Schaeffer EM. Calais J. Boutros PC. Reiter RE. Molecular hallmarks of prostate-specific membrane antigen in treatment-naïve prostate cancer. Eur Urol. 2024 Dec;86(6):579-587. PMID: 39294048
12. Weiner AB. Nguyen AV. Kishan AU. Reiter RE. Litwin MS. International variations in adherence to quality metrics for local-regional prostate cancer. Eur Urol Oncol. 2024 Dec;7(6):1469-1477. PMID: 38851994
13. Weiner AB. Kakani P. Armstrong AJ. Bossi A. Cornford P. Feng F. Kanabur P. Karnes RJ. McKay RR. Morgan TM. Schaeffer EM. Shore N. Tree AC. Spratt DE. Risk stratification of patients with recurrence after primary treatment for prostate cancer: A systematic review. Eur Urol. 2024 Sep;86(3):200-210. PMID: 38782697
14. Weiner AB. Agrawal R. Valle LF. Sonni I. Kishan AU. Rettig MB. Raman SS. Calais J. Boutros PC. Reiter RE. Impact of PSMA PET on Prostate Cancer Management. Curr Treat Options Oncol. 25(2):191-205. Feb 2024. PMID: 38270802
15. Weiner AB. Liu Y. Hakansson A. Zhao X. Proudfoot JA. Ho J. Zhang JH. Li EV. Karnes RJ. Den RB. Kishan AU. Reiter RE. Hamid AA. Ross AE. Tran PT. Davicioni E. Spratt DE. Attard G. Lotan TL. Chua MLK. Sweeney CJ. Schaeffer EM. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes. Cancer. 129(14):2169-2178. Jul 2023. PMID: 37060201
16. Weiner AB. Yu CY. Kini M. Liu Y. Davicioni E. Mitrofanova A. Lotan TL. Schaeffer EM. High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments. Prostate Cancer Prostatic Dis. 26(1):105-112. Mar 2023. PMID: 35568781
17. Weiner AB. Liu Y. Li EV. Zhao X. Li Z. Davicioni E. Lotan TL. Schaeffer EM. A transcriptomic model for homologous recombination deficiency in prostate cancer. Prostate Cancer Prostatic Dis. 25(4):659-665. April 2022. PMID: 34226663
18. Weiner AB. Vidotto T. Liu Y. Faisal FA. Murali S. McFarlane M. Imada EL. Zhao X. Li Z. Davicioni E. Marchionni L. Chinnaiyan AM. Freedland SJ. Spratt DE. Wu JD. Lotan TL. Schaeffer EM. Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nat Commun. 12(1):935. Feb 2021. PMID: 33568675
19. Weiner AB. Li EV. Desai AS. Press DJ. Schaeffer EM. Cause of death during prostate cancer survivorship: A contemporary US population-based analysis. Cancer. 127(16):2895-2904. Aug 2021. PMID: 33882145
Recent Publications
